Dennis Brown - Kintara Therapeutics Chief Scientific Officer, Director
Director
Dr. Dennis M. Brown Ph.D.is Chief Scientific Officer, Director of the Company. He was our Chief Scientific Officer since January 25, 2013 and a director of the Company since February 11, 2013. Dr. Brown is not standing for reelection at the Annual Meeting. Dr. Brown is one of our founders and has served as Chief Scientific Officer and director of Del Mar Pharmaceuticals Ltd. since inception. Dr. Brown has more than thirty years of drug discovery and development experience. He has served as Chairman of Mountain View Pharmaceuticals board of directors since 2000 and is the President of Valent. In 1999 he founded ChemGenex Therapeutics, which merged with a publicly traded Australian company in 2004 to become ChemGenex Pharmaceuticals, of which he served as President and a Director until 2009. He was previously a cofounder of Matrix Pharmaceutical, Inc., where he served as Vice President of Scientific Affairs from 19851995 and as VP, Discovery Research, from 19951999. He also previously served as an Assistant Professor of Radiology at Harvard University Medical School and as a Research Associate in Radiology at Stanford University Medical School. He received his B.A. in Biology and Chemistry, M.S. in Cell Biology and Ph.D. in Radiation and Cancer Biology, all from New York University. Dr. Brown is an inventor of about 34 issued U.S. patents and applications, many with foreign counterparts. since 2013.
| Age | 67 |
| Tenure | 11 years |
| Phone | 858-350-4364 |
| Web | http://www.delmarpharma.com |
Kintara Therapeutics Management Efficiency
The company has return on total asset (ROA) of (136.86) % which means that it has lost $136.86 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (316.72) %, meaning that it created substantial loss on money invested by shareholders. Kintara Therapeutics' management efficiency ratios could be used to measure how well Kintara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Thomas Waechter | NETGEAR | 64 | |
| Yves Istel | Analog Devices | 79 | |
| Matthew Behrent | Asure Software | 46 | |
| Richard Baudouin | Air Transport Services | 66 | |
| Grady Summers | NETGEAR | 39 | |
| Phyllis Campbell | Alaska Air Group | 66 | |
| Dhiren Fonseca | Alaska Air Group | 56 | |
| John Teets | Air Transport Services | 45 | |
| James Champy | Analog Devices | 75 | |
| James Thompson | Alaska Air Group | 70 | |
| Helvi Sandvik | Alaska Air Group | 66 | |
| Adrian Pertierra | Asure Software | 45 | |
| Robert Coretz | Air Transport Services | 54 | |
| Jef Graham | NETGEAR | 60 | |
| Bradley Maiorino | NETGEAR | 47 | |
| Charles Lathrop | Asure Software | 61 | |
| Katherine SavittLennon | Alaska Air Group | 51 | |
| Randall Waterfield | Asure Software | 43 | |
| Joycelyn CarterMiller | NETGEAR | 56 | |
| Raymond Conner | Alaska Air Group | 65 | |
| Ali Husain | Analog Devices | N/A | |
Management Performance
| Return On Equity | -316.72 | |||
| Return On Asset | -136.86 |
Kintara Therapeutics Leadership Team
Elected by the shareholders, the Kintara Therapeutics' board of directors comprises two types of representatives: Kintara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kintara. The board's role is to monitor Kintara Therapeutics' management team and ensure that shareholders' interests are well served. Kintara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kintara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scott Praill, CFO and Principal Accounting Officer | ||
| John Bell, Independent Director | ||
| William Garner, Director | ||
| Erich Mohr, Independent Director | ||
| Saiid Zarrabian, Director | ||
| Robert Toth, Director | ||
| Dennis Brown, Chief Scientific Officer, Director | ||
| Jeffrey Bacha, President CEO, Director | ||
| Lynda Cranston, Independent Director | ||
| Robert Hoffman, Independent Director | ||
| Napoleone Ferrara, Director |
Kintara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kintara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -316.72 | |||
| Return On Asset | -136.86 | |||
| Current Valuation | 13.09 M | |||
| Shares Outstanding | 11.46 M | |||
| Shares Owned By Insiders | 1.44 % | |||
| Shares Owned By Institutions | 12.46 % | |||
| Number Of Shares Shorted | 246.63 K | |||
| Price To Earning | (1.68) X | |||
| Price To Book | 3.26 X | |||
| EBITDA | (8.26 M) |
Pair Trading with Kintara Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kintara Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kintara Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Prologis could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Prologis when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Prologis - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Prologis to buy it.
The correlation of Prologis is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Prologis moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Prologis moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Prologis can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |